A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or In Combination With Metformin)

Percent Change From Baseline in Index of Static Beta-Cell Sensitivity to Glucose at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]

Static sensitivity is a measure of the effect of glucose on beta-cell secretion and is the ratio between the insulin secretion rate and glucose concentration above the threshold level at steady state. (See Breda and Cobelli, Annals of Biomedical Engineering 29, 692-700 (2001) for more details.)

Patient is poorly controlled while on insulin or insulin and metformin

Exclusion Criteria:

Patient has a history of type 1 diabetes mellitus or history of ketoacidosis

Patient is taking oral antidiabetic agents other than metformin during the past 3 months

Patient is currently on treatment with daily use of pre-prandial short-acting or rapid-acting insulin

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00395343